North America Dengue Treatment Market

List of Tables

North America dengue treatment market is expected to reach USD 311.62 million by 2031, from USD 143.29 million in 2023, growing at the CAGR of 10.2% in the forecast period of 2024 to 2031.

Market Segmentation:

North America Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031

Overview of North America Dengue Treatment Market Dynamics:

Driver
Rising dengue incidence rate result in the demand for effective treatment
Restrain
Delay in the approval process of vaccines
Opportunity
Growing number of pipeline vaccines for dengue treatment

Market Players:

The key market players operating in the North America dengue treatment market are listed below:

Sanofi
Takeda Pharmaceutical Company Limited
Viatris Inc.
Johnson & Johnson
GSK plc.
Perrigo Company PLC
Baxter
Fresenius Kabi USA
Pfizer
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA, Inc.
Aurobindo Pharma

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA DENGUE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES

5 NORTH AMERICA DENGUE TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

6 MARKET OVERVIEW

6.1 DRIVERS
- 6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
- 6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
- 6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
- 6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
6.2 RESTRAINTS
- 6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
- 6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
- 6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
6.3 OPPORTUNITIES
- 6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
- 6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
- 6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
6.4 CHALLENGES
- 6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
- 6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS

7.1 OVERVIEW
7.2 DENV-2
7.3 DENV-3
7.4 DENV-1
7.5 DENV-4
7.6 OTHERS

8 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE

8.1 OVERVIEW
8.2 VACCINES
- 8.2.1 DENGVAXIA (CYD-TDV)
- 8.2.2 QDENGA
8.3 ACETAMINOPHEN
- 8.3.1 PARENTERAL
- 8.3.2 ORAL
- 8.3.3 OTHER

9 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY

9.1 OVERVIEW
9.2 MILD TO MODERATE DENGUE
9.3 SEVERE DENGUE

10 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW
10.2 PARENTERAL
- 10.2.1 SUB-CUTANEOUS
- 10.2.2 INTRAVENOUS
10.3 ORAL
- 10.3.1 TABLET
- 10.3.2 CAPSULES
- 10.3.3 OTHERS

11 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER-THE-COUNTER (OTC)

12 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER

12.1 OVERVIEW
12.2 MALE
12.3 FEMALE

13 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE

13.1 OVERVIEW
13.2 ADULT
13.3 PEDIATRIC
13.4 GERIATRIC

14 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER

14.1 OVERVIEW
14.2 HOSPITAL
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS

15 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES

16 NORTH AMERICA DENGUE TREATMENT MARKET, BY REGION

16.1 NORTH AMERICA
- 16.1.1 MEXICO
- 16.1.2 U.S.
- 16.1.3 CANADA

17 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 SANOFI
- 19.1.1 COMPANY SNAPSHOT
- 19.1.2 REVENUE ANALYSIS
- 19.1.3 COMPANY SHARE ANALYSIS
- 19.1.4 PRODUCT PORTFOLIO
- 19.1.5 RECENT DEVELOPMENTS
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 19.2.1 COMPANY SNAPSHOT
- 19.2.2 REVENUE ANALYSIS
- 19.2.3 COMPANY SHARE ANALYSIS
- 19.2.4 PRODUCT PORTFOLIO
- 19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
- 19.3.1 COMPANY SNAPSHOT
- 19.3.2 REVENUE ANALYSIS
- 19.3.3 COMPANY SHARE ANALYSIS
- 19.3.4 PRODUCT PORTFOLIO
- 19.3.5 RECENT DEVELOPMENTS
19.4 JOHNSON & JOHNSON SERVICES, INC.
- 19.4.1 COMPANY SNAPSHOT
- 19.4.2 REVENUE ANALYSIS
- 19.4.3 COMPANY SHARE ANALYSIS
- 19.4.4 PRODUCT PORTFOLIO
- 19.4.5 RECENT DEVELOPMENT
19.5 GSK PLC.
- 19.5.1 COMPANY SNAPSHOT
- 19.5.2 REVENUE ANALYSIS
- 19.5.3 COMPANY SHARE ANALYSIS
- 19.5.4 PRODUCT PORTFOLIO
- 19.5.5 RECENT DEVELOPMENTS
19.6 AUROBINDO PHARMA
- 19.6.1 COMPANY SNAPSHOT
- 19.6.2 REVENUE ANALYSIS
- 19.6.3 PRODUCT PORTFOLIO
19.7 BAXTER
- 19.7.1 COMPANY SNAPSHOT
- 19.7.2 REVENUE ANALYSIS
- 19.7.3 PRODUCT PORTFOLIO
19.8 FRESENIUS KABI USA
- 19.8.1 COMPANY SNAPSHOT
- 19.8.2 PRODUCT PORTFOLIO
- 19.8.3 RECENT DEVELOPMENTS
19.9 HIKMA PHARMACEUTICALS
- 19.9.1 COMPANY SNAPSHOT
- 19.9.2 REVENUE ANALYSIS
- 19.9.3 PRODUCT PORTFOLIO
- 19.9.4 RECENT DEVELOPMENT
19.10 PERRIGO COMPANY PLC
- 19.10.1 COMPANY SNAPSHOT
- 19.10.2 REVENUE ANALYSIS
- 19.10.3 PRODUCT PORTFOLIO
- 19.10.4 RECENT DEVELOPMENT
19.11 PFIZER INC.
- 19.11.1 COMPANY SNAPSHOT
- 19.11.2 REVENUE ANALYSIS
- 19.11.3 PRODUCT PORTFOLIO
- 19.11.4 RECENT DEVELOPMENTS
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
- 19.12.1 COMPANY SNAPSHOT
- 19.12.2 REVENUE ANALYSIS
- 19.12.3 PRODUCT PORTFOLIO
- 19.12.4 RECENT DEVELOPMENT
19.13 TEVA PHARMACEUTICALS USA, INC.
- 19.13.1 COMPANY SNAPSHOT
- 19.13.2 REVENUE ANALYSIS
- 19.13.3 PRODUCT PORTFOLIO
- 19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 4 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 13 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 14 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 17 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 18 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 NORTH AMERICA ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 50 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 51 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 53 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 54 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 60 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 63 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 64 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 67 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 68 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 70 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 72 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 73 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 76 MEXICO DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 77 MEXICO DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 78 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 80 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 81 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 84 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 85 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 87 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 88 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 89 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 90 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 93 U.S. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 94 U.S. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 95 U.S. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 96 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 98 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 101 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 102 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 104 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 105 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 106 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 107 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 CANADA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 110 CANADA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 111 CANADA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 112 CANADA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

LIST OF FIGURES

FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE NORTH AMERICA DENGUE TREATMENT MARKET FROM 2024 TO 2031
FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA DENGUE TREATMENT MARKET
FIGURE 14 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2023
FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2023
FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2023
FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY GENDER, 2023
FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY AGE, 2023
FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2023
FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 53 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)